Major Depressive Disorder
MDD · Neurology · 3 drugs · 1 indications
Persistent depressive disorder characterized by low mood, loss of interest, and cognitive impairment lasting at least 2 weeks.
Competitive Landscape (3 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Centanafadine | 4578 | Triple Reuptake Inhibitor (NDSRI) | Small molecule | ORAL | FILED |
| Ulotaront | 4578 | TAAR1/5-HT1A Agonist | Small molecule | ORAL | PHASE3 |
| Rexulti | 4578 | Serotonin-Dopamine Activity Modulator (SDAM) | Small molecule | ORAL | APPROVED |
Indications (1)
Upcoming Catalysts
Ulotaront - Schizophrenia - Ph3 - Relapse Prevention (DIAMOND 5)CLINICAL
4578H2 2026
Centanafadine - ADHD - FDA PDUFA DecisionREGULATORY
4578July 24, 2026
Data from Supabase · Updated 2026-03-24